Depression
Conditions
Keywords
Inflammation, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Brief summary
The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.
Detailed description
Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin decreases the risk, especially among patients with increased inflammation. This is a proof-of-concept study to investigate whether the antiinflammatory effect of rosuvastatin is similar in depressive as in patients with cardiovascular disease.
Interventions
DRUGrosuvastatin
10mg tablets, once daily in three months
DRUGPlacebo
tablet, once daily, three months
Sponsors
University Hospital, Akershus
Oslo University Hospital
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Persisting self-reported depressive symptoms \> 5 weeks * Indications of aortic atherosclerosis on PET/CT
Exclusion criteria
* Clinical indication of statin use. * Contraindication of statins, or of PET/CT and MRI. * Established cardiovascular disease. * Bipolar disorder og comorbid psychosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean SUV of large arteries | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral endothelial function (pulse wave amplitude) | 3 months |
| Circulatory proinflammatory markers | 3 months |
| Heart rate variability | 3 months |
| Depressive symptoms | 3 months |
Countries
Norway
Outcome results
None listed